Author | Ravi Salgia, MD, PhD | OncLive

Author | Ravi Salgia, MD, PhD

Articles

Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC

November 03, 2018

Video

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

February 19, 2018

Video

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

Dr. Salgia on Importance of Molecular Markers in Lung Cancer

February 01, 2018

Video

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Dr. Salgia on Next-Generation Sequencing in Lung Cancer

January 02, 2018

Video

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

x